1. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy.
- Author
-
Adkison JB, Tomé W, Seo S, Richards GM, Robins HI, Rassmussen K, Welsh JS, Mahler PA, and Howard SP
- Subjects
- Adolescent, Adult, Age Factors, Aged, Brain Neoplasms mortality, Brain Neoplasms pathology, Child, Dose Fractionation, Radiation, Female, Glioma mortality, Glioma pathology, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Radiotherapy methods, Retreatment, Survival Analysis, Time Factors, Tumor Burden, Young Adult, Brain Neoplasms radiotherapy, Glioma radiotherapy, Neoplasm Recurrence, Local radiotherapy
- Abstract
Purpose: Pulsed reduced-dose-rate radiotherapy (PRDR) is a reirradiation technique that reduces the effective dose rate and increases the treatment time, allowing sublethal damage repair during irradiation., Patients and Methods: A total of 103 patients with recurrent glioma underwent reirradiation using PRDR (86 considered to have Grade 4 at PRDR). PRDR was delivered using a series of 0.2-Gy pulses at 3-min intervals, creating an apparent dose rate of 0.0667 Gy/min to a median dose of 50 Gy (range, 20-60) delivered in 1.8-2.0-Gy fractions. The mean treatment volume was 403.5±189.4 cm3 according to T2-weighted magnetic resonance imaging and a 2-cm margin., Results: For the initial or upgraded Grade 4 cohort (n=86), the median interval from the first irradiation to PRDR was 14 months. Patients undergoing PRDR within 14 months of the first irradiation (n=43) had a median survival of 21 weeks. Those treated ≥14 months after radiotherapy had a median survival of 28 weeks (n=43; p=0.004 and HR=1.82 with a 95% CI ranging from 1.25 to 3.10). These data compared favorably to historical data sets, because only 16% of the patients were treated at first relapse (with 46% treated at the second relapse, 32% at the third or fourth relapse, and 4% at the fourth or fifth relapse). The median survival since diagnosis and retreatment was 6.3 years and 11.4 months for low-grade, 4.1 years and 5.6 months for Grade 3, and 1.6 years and 5.1 months for Grade 4 tumors, respectively, according to the initial histologic findings. Multivariate analysis revealed age at the initial diagnosis, initial low-grade disease, and Karnofsky performance score of ≥80 to be significant predictors of survival after initiation of PRDR., Conclusion: PRDR allowed for safe retreatment of larger volumes to high doses with palliative benefit., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF